Compare DraftKings Inc (DKNG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Recursion Pharmaceuticals Inc — how do they compare? DraftKings Inc trades at $19.9 (market cap $9.51B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.31B). The key difference: DraftKings Inc is far larger — about 4.1× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, DraftKings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DraftKings Inc for 55 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| DKNG | RXRX | |
|---|---|---|
Market Cap | $9.51B | $2.31B |
Volume | 11,829,779 | 40,478,768 |
Sector | Consumer Cyclical | Health |
52-Week High | $36.24 | $6.79 |
52-Week Low | $18.59 | $2.84 |
Typical Hold Time | 55 Days | 22 Days |
Enterprise Value | $10.44B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $19.87, near its 52-week low, with a bearish technical outlook despite strong analyst support. The company achieved profitability in 2025 with $6.05B revenue and positive net income of $3.71M, though recent quarters show earnings misses. Operating cash flow improved to $663M in 2025, but high valuation multiples (P/E 246.33) and negative ROE (-22.12%) highlight risks. Recent news focuses on prediction market expansion and NFL season performance.
The stock faces near-term pressure from technical weakness and earnings volatility, but long-term growth drivers in sports betting and predictions remain intact. Wall Street maintains strong bullish sentiment with a $33.13 price target, though investors should weigh high valuation against execution risks and competitive threats in the evolving gaming landscape.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
